CA2781255C - Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms - Google Patents

Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms Download PDF

Info

Publication number
CA2781255C
CA2781255C CA2781255A CA2781255A CA2781255C CA 2781255 C CA2781255 C CA 2781255C CA 2781255 A CA2781255 A CA 2781255A CA 2781255 A CA2781255 A CA 2781255A CA 2781255 C CA2781255 C CA 2781255C
Authority
CA
Canada
Prior art keywords
hemoglobin
antibody
seq
subpopulation
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2781255A
Other languages
English (en)
French (fr)
Other versions
CA2781255A1 (en
Inventor
Roger Walker
Benedicte Jardin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Laboratories Inc
Original Assignee
Bio Rad Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Rad Laboratories Inc filed Critical Bio Rad Laboratories Inc
Publication of CA2781255A1 publication Critical patent/CA2781255A1/en
Application granted granted Critical
Publication of CA2781255C publication Critical patent/CA2781255C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2781255A 2009-11-18 2010-11-09 Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms Active CA2781255C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26248809P 2009-11-18 2009-11-18
US61/262,488 2009-11-18
US12/941,738 US8603828B2 (en) 2009-11-18 2010-11-08 Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
US12/941,738 2010-11-08
PCT/US2010/055952 WO2011062803A2 (en) 2009-11-18 2010-11-09 Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms

Publications (2)

Publication Number Publication Date
CA2781255A1 CA2781255A1 (en) 2011-05-26
CA2781255C true CA2781255C (en) 2017-08-01

Family

ID=44011571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2781255A Active CA2781255C (en) 2009-11-18 2010-11-09 Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms

Country Status (8)

Country Link
US (5) US8603828B2 (https=)
EP (3) EP3301452B1 (https=)
JP (2) JP6139886B2 (https=)
AU (3) AU2010322233B2 (https=)
CA (1) CA2781255C (https=)
ES (1) ES2665958T3 (https=)
PT (1) PT3043182T (https=)
WO (1) WO2011062803A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603828B2 (en) * 2009-11-18 2013-12-10 Bio-Rad Laboratories, Inc. Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
US10976326B2 (en) 2013-12-26 2021-04-13 Kyocera Corporation Sensor
US10520515B2 (en) * 2014-03-20 2019-12-31 Bio-Rad Laboratories, Inc. Glycated protein assay
EP3129789B1 (en) 2014-04-11 2019-10-23 Siemens Healthcare Diagnostics Inc. Spectroscopic methods for the detection of glycated hemoglobin
US20160116489A1 (en) * 2014-10-23 2016-04-28 Biomedomics, Inc. Lateral flow immunoassay method of simultaneously detecting hemoglobin s, hemoglobin c, and hemoglobin a in newborns, infants, children, and adults
US10545158B2 (en) 2014-12-29 2020-01-28 North Carolina State University Multiplexed diagnostic to recognize concentrations of related proteins and peptides
EP3256850B1 (en) 2015-02-09 2025-07-09 Slingshot Biosciences, Inc. Hydrogel particles with tunable optical properties and methods for using the same
JP6492856B2 (ja) * 2015-03-25 2019-04-03 東ソー株式会社 安定型糖化ヘモグロビンＡ１ｃの定量方法
WO2017070364A1 (en) * 2015-10-21 2017-04-27 Qoolabs, Inc. Camelid hemoglobin antibodies and methods of use
US10670615B2 (en) 2015-12-04 2020-06-02 Polymer Technology Systems, Inc. Systems and methods for interference correction from hemoglobin variants
WO2017141514A1 (ja) 2016-02-17 2017-08-24 株式会社デンソー 車両用空調ユニット
US12345718B2 (en) * 2016-11-04 2025-07-01 Université Paris Est Créteil Val De Marne Method for determining the haemoglobin content of an erythroid cell
US10317413B2 (en) 2016-11-14 2019-06-11 The Board Of Regents Of The University Of Texas System Method and kit for detection of anti-zika virus antibodies
MA51152A (fr) * 2017-12-15 2020-10-21 Bluebird Bio Inc Anticorps de bêta-globine falciformes
AU2019301750A1 (en) 2018-07-12 2021-01-28 Board Of Regents, The University Of Texas System Molecular neighborhood detection by oligonucleotides
WO2020067396A1 (ja) * 2018-09-28 2020-04-02 積水メディカル株式会社 糖化ヘモグロビン（％）の測定方法
GB2593091B (en) 2018-10-05 2023-12-20 Univ Texas Solid-phase N-terminal peptide capture and release
US20220163543A1 (en) * 2019-03-04 2022-05-26 Siemens Healthcare Diagnostics Inc. Dried reagent polysaccharide surface area stabilization
US20200284807A1 (en) * 2019-03-05 2020-09-10 Victor Manneh Saturation binding ratiometric assay
JP7759328B2 (ja) 2020-01-24 2025-10-23 スリングショット バイオサイエンシーズ， インコーポレイテッド 細胞様較正粒子のための組成物および方法
CA3177834A1 (en) 2020-05-04 2021-11-11 Jeffrey Kim Compositions and methods for passive optical barcoding for multiplexed assays
JP2024539956A (ja) 2021-10-29 2024-10-31 スリングショット バイオサイエンシーズ， インコーポレイテッド フィーダー細胞としておよび合成抗原提示細胞としてのヒドロゲル粒子
JPWO2023195348A1 (https=) * 2022-04-04 2023-10-12
WO2023196898A1 (en) * 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CN119907921A (zh) 2022-05-05 2025-04-29 弹弓生物科学公司 用于血液学的作为红细胞模拟物的工程化颗粒和含有工程化颗粒的组合物
AU2023280490A1 (en) 2022-06-02 2024-12-05 Slingshot Biosciences, Inc. Apoptotic cell mimic
EP4608872A2 (en) 2022-10-26 2025-09-03 Slingshot Biosciences, Inc. Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation
WO2025049609A1 (en) 2023-08-29 2025-03-06 Slingshot Biosciences, Inc. Cd34 stem cell mimics

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2632478A1 (de) 1975-07-23 1977-02-24 Coulter Electronics Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben
US4752583A (en) * 1984-11-29 1988-06-21 The United States Of America As Represented By The United States Department Of Energy Monoclonal antibodies to human hemoglobin S and cell lines for the production thereof
US5428754A (en) 1988-03-23 1995-06-27 3Dlabs Ltd Computer system with clock shared between processors executing separate instruction streams
US5922854A (en) * 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
AU3737093A (en) 1992-03-04 1993-10-05 Abbott Laboratories Determination of glycated hemoglobin by fluorescence quenching
US6043043A (en) * 1993-04-02 2000-03-28 Bayer Corporation Method for the determination of hemoglobin adducts
US6951716B2 (en) 1995-03-13 2005-10-04 Mark Hechinger Anti-platelet immunoglobulin bead positive control
US6933106B2 (en) 1995-03-13 2005-08-23 Mark Hechinger Platelet immunoglobulin bead suspension and flow cytometry
JP2001516567A (ja) * 1997-09-19 2001-10-02 セレックス， インコーポレイテッド 抗原の免疫原性および抗体の特異性を改善する方法
EP0965044B1 (en) 1997-11-18 2003-03-19 Bio-Rad Laboratories, Inc. Multiplex flow immunoassays with magnetic particles as solid phase
US7271009B1 (en) * 1997-11-18 2007-09-18 Bio-Rad Laboratories, Inc. Multi-analyte diagnostic test for thyroid disorders
JP4318859B2 (ja) 1997-12-04 2009-08-26 ジーイー・ヘルスケア・ユーケイ・リミテッド 複合アッセイ方法
US20020115116A1 (en) 2001-02-22 2002-08-22 Yong Song Multiplex protein interaction determinations using glutathione-GST binding
EP1414860B1 (en) * 2001-04-26 2009-12-30 Dako Denmark A/S Anti-glycated hemoglobin pan-specific monoclonal antibody
WO2003087768A2 (en) * 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US7326573B2 (en) 2003-01-10 2008-02-05 Beckman Coulter, Inc. Assay procedures and apparatus
WO2004074452A2 (en) 2003-02-19 2004-09-02 The Regents Of The University Of California Multiplex mapping of protein interactions
US20040214243A1 (en) * 2003-04-25 2004-10-28 Beckman Coulter, Inc. Differential determination of hemoglobins
US7150995B2 (en) 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
US20080108144A1 (en) * 2004-05-27 2008-05-08 Alam Muhammad A Method for the Rapid Analysis of Polypeptides
JP2006052480A (ja) 2004-08-10 2006-02-23 Nisshinbo Ind Inc セルロース系繊維含有布帛の加工方法及びセルロース系繊維含有布帛
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
CA2610780A1 (en) 2005-06-03 2006-12-07 Nipro Corporation High-copy-number, high-expression vector having methionine aminopeptidase gene therein
US7521244B2 (en) * 2006-10-26 2009-04-21 Bionostics, Inc. Standard reference solutions
ES2541114T3 (es) * 2007-11-20 2015-07-16 Siemens Healthcare Diagnostics Inc. Métodos para la detección de hemoglobina glicosilada
US8260556B2 (en) 2008-08-21 2012-09-04 Bio-Rad Laboratories, Inc. Calibration surface method for determination on of analyte ratios
WO2011003182A1 (en) * 2009-07-07 2011-01-13 University Of Victoria Innovation And Development Corporation Methods for early detection of blood disorders
US8603828B2 (en) 2009-11-18 2013-12-10 Bio-Rad Laboratories, Inc. Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms

Also Published As

Publication number Publication date
EP3043182B1 (en) 2018-01-17
EP3043182A1 (en) 2016-07-13
US10088488B2 (en) 2018-10-02
ES2665958T3 (es) 2018-04-30
US9605060B2 (en) 2017-03-28
AU2017200733A1 (en) 2017-02-23
US20170176462A1 (en) 2017-06-22
WO2011062803A3 (en) 2011-07-28
US11262366B2 (en) 2022-03-01
AU2019200070A1 (en) 2019-01-31
PT3043182T (pt) 2018-04-23
EP2502080A2 (en) 2012-09-26
US20190018023A1 (en) 2019-01-17
US20160068594A1 (en) 2016-03-10
EP3301452B1 (en) 2020-01-08
JP2013511717A (ja) 2013-04-04
US20110117670A1 (en) 2011-05-19
EP2502080B1 (en) 2016-04-13
US20140073532A1 (en) 2014-03-13
EP2502080A4 (en) 2013-03-27
AU2019200070B2 (en) 2020-07-16
US8603828B2 (en) 2013-12-10
AU2010322233B2 (en) 2016-11-03
AU2010322233A1 (en) 2012-06-21
US9213034B2 (en) 2015-12-15
JP6139886B2 (ja) 2017-05-31
EP3301452A1 (en) 2018-04-04
AU2017200733B2 (en) 2018-10-11
JP2016028254A (ja) 2016-02-25
CA2781255A1 (en) 2011-05-26
WO2011062803A2 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
AU2019200070B2 (en) Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
US20210088517A1 (en) MULTIPLEX HIGH-THROUGHPUT FLOW CYTOMETRY DETECTION OF SARS-COV-2-SPECIFIC IgG, IgA AND IgM
EP2864787B1 (en) Human factor xiii as a normalization control for immunoassays
EP3859332B1 (en) Glycated hemoglobin (%) assay method
JP5199067B2 (ja) 免疫凝集反応試薬キット及び抗原の測定方法
CA2939789C (en) Red blood cell detection
KR102016188B1 (ko) 교정제 및 교정 방법
CA2642634A1 (en) Novel assay for the detection of an antibody bound to a cell membrane receptor
CN120504740A (zh) 一种促甲状腺激素抗体及其在荧光免疫层析检测中的应用
CN115951072A (zh) 一种糖化血红蛋白-c肽联合检测试剂盒
WO2003080676A1 (fr) Anticorps contre un complexe immun contenant de la transferine, methode de production de l'anticorps, hybridome et methode de dosage immunologique

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250509